Briefly, it's not an area in which I have a lot of expertise. The Council of Canadians has read the studies from the generics association about increased drug costs, for example, and that would be based, as I understand it, on the amount of time it would require a new drug to get to market following the implementation of these intellectual property reforms, which are, as you said, entirely one-sided. There have been European requests, and Canada has been asked to take it or leave it. It sounds as though Canada's been asked to take it, with no option to leave it in these negotiations, because it's that important for European negotiators.
As I understand it, Canada's IP regime is based on a balance, recognizing the importance of both sectors--generics and the brand-name industry. If you have one sector saying this is actually going to benefit only the brand-name sector, then I think Canadians and this committee should consider the balance and the necessity of really dealing with this in the legislative, domestic way and not having a trade agreement impose changes to Canada's IP regime.